Patents by Inventor Harpreet Singh

Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200291084
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Helen HOERZER, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Patent number: 10766944
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 8, 2020
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10765730
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: September 8, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10769352
    Abstract: The present disclosure is directed toward systems, methods, and computer readable media for providing dynamic digital content via a webpage without flicker. For example, systems described herein include receiving a web document including action items associated with rendering dynamic digital content via a display device. The systems and methods described herein can reduce flicker in rendering the dynamic digital content by identifying dynamic digital content, pre-fetching external resources, and selectively hiding dynamic visual elements. In addition, the systems and methods described herein further reduce flicker by generating a dependency graph that reflects dependencies between the action items and then rendering digital content in accordance with an action queue generated based on the dependency graph. Furthermore, systems can individually reveal dynamic visual elements as action items for rendering dynamic digital content via the dynamic visual elements from the dependency graph are completed.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: September 8, 2020
    Assignee: ADOBE INC.
    Inventors: Harpreet Singh, Sachin Jain, Lalit Kishore Sharma
  • Publication number: 20200272112
    Abstract: Provided is a system and method for training and validating models in a machine learning pipeline for failure mode analytics. The machine learning pipeline may include an unsupervised training phase, a validation phase and a supervised training and scoring phase. In one example, the method may include receiving a request to create a machine learning model for failure mode detection associated with an asset, retrieving historical notification data of the asset, generating an unsupervised machine learning model via unsupervised learning on the historical notification data, wherein the unsupervised learning comprises identifying failure topics from text included in the historical notification data and mapping the identified failure topics to a plurality of predefined failure modes for the asset, and storing the generated unsupervised machine learning model via a storage device.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 27, 2020
    Inventors: Lukas Carullo, Patrick Brose, Kun Bao, Anubhav Bhatia, Rashmi Shetty B, Leonard Brzezinski, Lauren McMullen, Harpreet Singh, Karthik Mohan Mokashi, Simon Lee
  • Publication number: 20200268861
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 27, 2020
    Inventors: Toni WEINSCHENK, Jens FRITSCHE, Harpreet SINGH, Andrea MAHR, Martina OTT, Claudia WAGNER, Oliver SCHOOR
  • Publication number: 20200268863
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 27, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Helen HOERZER, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Patent number: 10745460
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: August 18, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Publication number: 20200254022
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 13, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20200254723
    Abstract: Laminate film structures including an adhesive layer having gas and moisture barrier properties are disclosed. The disclosed laminate film structures comprise films bonded together with an adhesive composition, the adhesive composition having barrier properties, e.g., controlling oxygen and/or water vapor transmission rates. The disclosed laminate film structures comprise films made from polymers and/or metallized polymers whereby the weight, thickness, and/or number of film layers has been reduced by using a barrier adhesive in place of a standard adhesive while still achieving similar barrier properties.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 13, 2020
    Inventors: Viraj Shah, Kalyan Sehanobish, Amira A. Marine, Brian Dorvel, Harpreet Singh, Hayley A. Brown
  • Publication number: 20200254017
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 3, 2020
    Publication date: August 13, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20200255490
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 13, 2020
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20200255491
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 13, 2020
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10738094
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 11, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20200247010
    Abstract: The present disclosure provides a process. The process includes (i) melt blending, in an extruder, (a) a polyolefin phase and (b) an aqueous phase in the presence of (c) at least one dispersant selected from an acrylic dispersant, a poloxamer dispersant, and combinations thereof; (ii) producing an interfacial tension from 0.1 dynes/cm to 25 dynes/cm; (iii) forming a polyolefin aqueous dispersion having from 25 wt % to 90 wt % solids content of dispersion; and (iv) removing the water from the polyolefin aqueous dispersion to form a powder. The powder has a mean volume average particle size from 10 ?m to 300 ?m, a sphericity from 0.92 to 1.0, a particle size distribution from 1 to less than 2, and a particle density from 98% to 100%.
    Type: Application
    Filed: October 22, 2018
    Publication date: August 6, 2020
    Inventors: Craig F. Gorin, Sanjib Biswas, Manesh Nadupparambil Sekharan, Thomas L. Tomczak, Robert S. Moglia, Daniel L. Dermody, Harpreet Singh, Bryan L. McCulloch
  • Patent number: 10729755
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 4, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Patent number: 10730222
    Abstract: The present disclosure provides a die assembly for producing a microcapillary film. The die assembly includes a first die plate, a second die plate, a plurality of multi-jackbolt tensioners connecting the first die plate to the second die plate, a manifold, and a plurality of nozzles. The manifold is located between the pair of die plates and defines a plurality of film channels therebetween. The plurality of film channels converge into an elongate outlet, wherein a thermoplastic material is extrudable through the plurality of film channels and the elongate outlet to form a microcapillary film. The plurality of nozzles are located between the plurality of film channels. The plurality of nozzles are operatively connected to a source of channel fluid for emitting the channel fluid between layers of the microcapillary film, whereby a plurality of microcapillary channels are formed in the microcapillary film.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 4, 2020
    Assignee: Dow Global Technologies LLC
    Inventors: Wenyi Huang, Jeffrey D. Wenzel, Jie Feng, Robert E. Wrisley, Hyunwoo Kim, Kurt A. Koppi, Scott R. Kaleyta, Thomas J. Parsons, Nicolas Cardoso Mazzola, Harpreet Singh
  • Patent number: 10726264
    Abstract: Techniques for localizing a device based on images captured by the device. The techniques include receiving, from a device via a data communication network, image frame data for frames captured by an imaging camera included in the device, the frames including a first frame, automatically detecting real-world objects captured in the image frame data, automatically classifying the detected real-world objects as being associated with respective object classes, automatically identifying object class and instance dependent keypoints for the real-world objects based on the object classes associated with the real-world objects, and estimating a pose of the device for the first frame based on at least the identified object class and instance dependent keypoints.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: July 28, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Harpreet Singh Sawhney, Marc André Léon Pollefeys
  • Patent number: 10723781
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: July 28, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10722566
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: July 28, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh